Gayathri Diwakar
Head of Investor Relations
Replay available
Crinetics Pharmaceuticals, Inc. (CRNX) Q3 2025 Earnings Call
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) Q3 2025 earnings conference call, held 2025-11-06. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Dr. Scott Struthers
Founder and Chief Executive Officer
Isabel Calafonos
Chief Commercial Officer
Toby Schilke
Chief Financial Officer
Dr. Alan Krasner
Chief Endocrinologist
Corey Chubinville
Analyst, LifeSci Capital
Catherine Novak
Analyst, Jones Trading
Yasmeen Rahimi
Analyst, Piper Sandler
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Crinetics Pharmaceuticals, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:04.416 And I'd like to turn the call over to Gayathri Diwakar, Head of Investor Relations. 00:00:04.416 -- 00:00:06.936 Please go ahead. 00:00:07.078 -- 00:00:11.423 Thank you, Operator. Good afternoon, everyone, and thank you for joining us to discuss 00:00:11.423 -- 00:00:15.828 the third quarter 2025 results. Today on the call, we have Dr. 00:00:15.828 -- 00:00:20.993 Scott Struthers, Founder and Chief Executive Officer, Isabel Calafonos, Chief 00:00:20.993 -- 00:00:24.557 Commercial Officer, and Toby Schilke, Chief Financial Officer. 00:00:24.557 -- 00:00:28.001 Also joining for the Q&A portion will be Dr. 00:00:28.001 -- 00:00:31.293 Steve Betts, Founder and Chief Scientific Officer, Dr. 00:00:31.293 -- 00:00:35.239 Dana Pizzuti, Chief Medical and Development Officer, and Dr. 00:00:35.239 -- 00:00:40.787 Alan Krasner, Chief Endocrinologist. Please note there's a slide deck for today's presentation, 00:00:40.787 -- 00:00:45.154 which is in the Events and Presentations section of the Investors page on the Clinetics 00:00:45.154 -- 00:00:50.422 website. In addition, a press release was issued earlier today and is also available 00:00:50.422 -- 00:00:56.070 on the corporate website. Slide two. As a reminder, we'll be making forward-looking statements, 00:00:56.070 -- 00:01:00.021 and I invite you to learn more about the risk and uncertainties associated with these 00:01:00.021 -- 00:01:03.705 statements as disclosed in our SEC filings. 00:01:03.705 -- 00:01:08.110 Such forward-looking statements are not a guarantee of performance, and the company's 00:01:08.110 -- 00:01:13.035 actual results could differ materially from those stated or implied in such statements 00:01:13.035 -- 00:01:16.999 due to risks and uncertainties associated with ...